Literature DB >> 2317626

Glucose metabolic rate in normals and schizophrenics during the Continuous Performance Test assessed by positron emission tomography.

M S Buchsbaum1, K H Nuechterlein, R J Haier, J Wu, N Sicotte, E Hazlett, R Asarnow, S Potkin, S Guich.   

Abstract

Local cerebral uptake of glucose labelled with fluorine-18 was measured by positron emission tomography in 13 patients with schizophrenia and 37 right-handed volunteers. Patients received no medication for a minimum of 31 days and a mean of 30 weeks. The subjects were administered the labelled deoxyglucose just after the beginning of a 32-minute sequence of blurred numbers as visual stimuli for the Continuous Performance Test. In normal controls, task performance was associated with increases in glucose metabolic rate in the right frontal and right temporoparietal regions; occipital rates were unchanged. Patients with schizophrenia showed both absolutely and relatively reduced metabolic rates in the frontal cortex and in the temporoparietal regions compared with normal controls.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2317626     DOI: 10.1192/bjp.156.2.216

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  42 in total

Review 1.  Hemisphere specialization as an aid in early infancy.

Authors:  Gordon Burnand
Journal:  Neuropsychol Rev       Date:  2002-12       Impact factor: 7.444

2.  Brief report: attention performance in autism and regional brain metabolic rate assessed by positron emission tomography.

Authors:  M S Buchsbaum; B V Siegel; J C Wu; E Hazlett; N Sicotte; R Haier; P Tanguay; R Asarnow; T Cadorette; D Donoghue
Journal:  J Autism Dev Disord       Date:  1992-03

3.  Dissociation of acute and chronic intermittent phencyclidine-induced performance deficits in the 5-choice serial reaction time task: influence of clozapine.

Authors:  David M Thomson; Allan McVie; Brian J Morris; Judith A Pratt
Journal:  Psychopharmacology (Berl)       Date:  2010-09-29       Impact factor: 4.530

Review 4.  Structural and functional brain imaging in schizophrenia.

Authors:  J M Cleghorn; R B Zipursky; S J List
Journal:  J Psychiatry Neurosci       Date:  1991-07       Impact factor: 6.186

Review 5.  Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Authors:  Jeffrey A Lieberman; Frank P Bymaster; Herbert Y Meltzer; Ariel Y Deutch; Gary E Duncan; Christine E Marx; June R Aprille; Donard S Dwyer; Xin-Min Li; Sahebarao P Mahadik; Ronald S Duman; Joseph H Porter; Josephine S Modica-Napolitano; Samuel S Newton; John G Csernansky
Journal:  Pharmacol Rev       Date:  2008-09       Impact factor: 25.468

Review 6.  [Cognitive disorders in schizophrenic patients].

Authors:  H-P Volz; F Reischies; M Riedel
Journal:  Nervenarzt       Date:  2010-01       Impact factor: 1.214

7.  Advances in endophenotyping schizophrenia.

Authors:  David L Braff; Tiffany A Greenwood; Neal R Swerdlow; Gregory A Light; Nicholas J Schork
Journal:  World Psychiatry       Date:  2008-02       Impact factor: 49.548

8.  The configural properties of task stimuli do influence vigilance performance.

Authors:  Neil R de Joux; Kyle Wilson; Paul N Russell; William S Helton
Journal:  Exp Brain Res       Date:  2015-05-31       Impact factor: 1.972

9.  A quantitative magnetic resonance imaging study of patients with schizophrenia.

Authors:  Y Kawasaki; Y Maeda; K Urata; M Higashima; N Yamaguchi; M Suzuki; T Takashima; Y Ide
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1993       Impact factor: 5.270

Review 10.  Markers of vulnerability in schizophrenia.

Authors:  Maria Ladea; Dan Prelipceanu
Journal:  J Med Life       Date:  2009 Apr-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.